[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570385":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Nicola Fusco, MD","Istituto Europeo di Oncologia","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","00390294372079","nicola.fusco@ieo.it",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"francesca lombardi, biologist","00390257489425","francesca.lombardi@ieo.it",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Milan","MI","20141","Italy","IT",{"type":31,"coordinates":32},"Point",[33,34],9.18951,45.46427,{"lat":34,"lon":33},[37],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100570385","analysis-of-circulating-tumor-dna-ctdna-in-her2-low-advancedmetastatic-breast-cancer-100570385",false,"NCT06706557","Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced\u002FMetastatic Breast Cancer","A Pilot Study on the Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced\u002FMetastatic Breast Cancer","LEGO","Inclusion Criteria\n\n* Participants diagnosed with HER2-low breast cancer, defined as IHC score 1+ or 2+ and not amplified at in situ hybridization (ISH) test as confirmed by local laboratory testing.\n* Participants should be at advanced or metastatic setting prior to treatment.\n* Written informed consent (Accordo di Partecipazione alla Ricerca Scientifica) and specific informed consent to the study must be signed and dated by the patient and the doctor prior to inclusion.\n* Patients must be accessible for follow-up.","FEMALE","18 Years",{"count":51,"type":52},30,"ESTIMATED","OBSERVATIONAL","A Pilot study on circulating tumor DNA (ctDNA) in advanced\u002Fmetastatic breast cancer with low levels of HER2 expression (HER2 low)",[56],"Advanced Metastatic Breast Cancer","2026-03-23",{"date":59,"type":60},"2026-03-24","ACTUAL",{"date":62,"type":60},"2024-01-11",{"date":64,"type":52},"2030-12-31",{"name":5,"class":6},1]